Sit Less, Interact and Move More (SLIMM) 2 Study

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 156 participants.

Also called NCT05173714

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 156 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05173714
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05173714. Randomized; quadruple masking; primary purpose treatment. Start 2021-12-01 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Sit Less, Interact and Move More (SLIMM) 2 Study
Condition
Chronic Kidney Diseases
Condition
Obesity
Intervention (Behavioral)
SLIMM
Intervention (Behavioral)
Standard Resistance Training
Intervention (Behavioral)
Guided Resistance Training
Intervention (Drug)
Placebo
Intervention (Drug)
Semaglutide
Lead sponsor
Srinvasan Beddhu (class: other)
Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (class: US National Institutes of Health)
Collaborator
Stanford University (class: other)

Record details

Record id
cardio:ct-nct05173714
Content hash
eb9e478d87bb6d7bd670b49b1232fd1152790a75399d219037bfc6c3b078f82e